Aminobenzoate Potassium Brand Name– Potaba
What is Aminobenzoate Potassium
Aminobenzoate potassium is an oral antifibrotic agent. It is the potassium salt of para-aminobenzoic acid (PABA) and is used to treat serious, often chronic diseases involving fibrosis and nonsuppurative inflammation.
The drug acts gradually, and length of therapy varies with disease state and extent of involvement. Therapy requires the maintenance of adequate dosage over a sufficient length of time, which is usually a minimum of 2 to 3 months.
This drug has been available since before 1938, prior to when Congress passed the 1962 amended Federal Food, Drug, and Cosmetic Act, requiring that the FDA establish both safety and efficacy for all subsequently approved drugs.
- Peyronie’s disease
Fever and rash (unspecified), possibly associated with allergic reaction, have been reported with use of aminobenzoate potassium. These adverse reactions appear to be infrequent and subside with omission of the drug. If necessary, desensitization can be accomplished and treatment resumed.
Anorexia, nausea, and vomiting have occurred infrequently with the use of aminobenzoate potassium. If any of these reactions occur, discontinue treatment until the patient is eating normally again.
- laboratory monitoring not necessary
- para-aminobenzoic acid, PABA hypersensitivity
- renal disease
- renal impairment
There are no drug interactions associated with Aminobenzoate Potassium products.